Boehringer Ingelheim v. Granules India: JENTADUETO Patent Action Dismissed in 16 Days
Boehringer Ingelheim filed a five-patent infringement action against Indian generics manufacturer Granules India over JENTADUETO linagliptin/metformin HCl tablets in the District of Delaware, then voluntarily withdrew all claims without prejudice just 16 days later — before the defendant had filed any responsive pleading.
Five-patent JENTADUETO suit withdrawn before Granules India responded
On 30 September 2024, three Boehringer Ingelheim entities — Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharma GmbH & Co. KG — filed an infringement action in the District of Delaware (Case No. 1:24-cv-01091) against Granules India Limited. The complaint asserted five US patents: US10022379B2, US11911388B2, US9415016B2, US10973827B2, and US9155705B2, all relating to JENTADUETO, Boehringer Ingelheim’s branded linagliptin/metformin hydrochloride combination tablet marketed in 2.5/500 mg, 2.5/850 mg, and 2.5/1000 mg strengths.
Just 16 days after filing, on 16 October 2024, the plaintiffs filed a notice of voluntary dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), dismissing all asserted claims without prejudice. The notice expressly confirmed that Granules India had not yet served an answer or motion for summary judgment at the time of filing, satisfying the procedural prerequisite for a unilateral voluntary dismissal. No court order was required, and no merits adjudication took place.
A 16-day lifespan is notably brief even by the standards of pharmaceutical ANDA litigation in Delaware, suggesting that either a settlement or licensing arrangement may have been reached rapidly, or that the filing itself was a tactical measure tied to the 30-month Hatch-Waxman stay clock. The public record does not disclose whether any commercial terms were agreed, and the without-prejudice nature of the dismissal preserves Boehringer Ingelheim’s right to re-file the same claims if future circumstances warrant — a potentially significant point for Granules India’s commercialisation timeline.
Filing to Voluntary dismissal in 16 days
16 days — among the shortest ANDA-related patent suits before voluntary dismissal in Delaware
Voluntarily dismissed: what the Rule 41 withdrawal means for both parties
Rule 41(a)(1)(A)(i) allows plaintiff to exit before any answer
Federal Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. Because Granules India had not yet responded, Boehringer Ingelheim was entitled to withdraw unilaterally. The dismissal takes effect immediately upon filing and requires no judicial approval.
Unilateral plaintiff dismissalWithout prejudice — the public record is silent on whether a deal was struck
A without-prejudice dismissal means the claims are not extinguished — Boehringer Ingelheim may re-file the same five-patent action against Granules India if circumstances change. This contrasts with a with-prejudice dismissal, which would bar re-filing on the same claims. The public record does not confirm whether a settlement, licence, or consent agreement underlies the withdrawal; the distinction matters significantly for Granules India’s commercial planning.
Re-filing rights preservedBoehringer Ingelheim retains full enforcement optionality
By dismissing without prejudice, Boehringer Ingelheim preserves its ability to reassert all five patents. If the withdrawal was tied to a Hatch-Waxman 30-month stay strategy or a commercial negotiation, the company retains leverage. No adverse ruling was entered, and the patent portfolio covering JENTADUETO formulations remains intact and unchallenged on the merits in this proceeding.
Portfolio intact, claims preservedGranules India faces continued uncertainty on US market entry
Granules India avoided any adverse judgment in this action, but the without-prejudice dismissal leaves it exposed to re-litigation. Without a confirmed licence or consent decree on record, Granules India cannot treat the dismissal as a commercial clearance. Any generic launch of linagliptin/metformin tablets in the US carries ongoing risk that Boehringer Ingelheim may reassert one or more of the five asserted patents.
Uncertainty remains for generic launchFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer Ingleheim Pharmaceuticals Inc. | Company | Multinational pharmaceutical group — holder of US10022379B2 and four further JENTADUETO patentsSearch in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingleheim International GMBH | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingleheim Pharma GMBH & Co. KG | Company | Search in Eureka ↗ |
| Defendant | Granules India Limited | Individual | Granules India Limited — Indian generics manufacturer seeking US market entry for linagliptin/metformin tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer Ingleheim Pharmaceuticals Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer Ingleheim Pharmaceuticals Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer Ingleheim Pharmaceuticals Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice is notable for its explicit reliance on Rule 41(a)(1)(A)(i) and its affirmative statement that no answer or summary judgment motion had been served. This procedural precision forecloses any argument that the defendant could have converted the dismissal or sought costs as a matter of right. The without-prejudice designation is the operative commercial term: it signals that the parties’ positions have not been adjudicated and that Boehringer Ingelheim’s enforcement options against Granules India remain open.
US10022379B2 and four further patents — JENTADUETO linagliptin/metformin combination
The five asserted patents — US10022379B2, US11911388B2, US9415016B2, US10973827B2, and US9155705B2 — collectively protect Boehringer Ingelheim’s JENTADUETO franchise, a fixed-dose combination of linagliptin (a DPP-4 inhibitor) and metformin hydrochloride for the management of type 2 diabetes. The patents span application dates ranging from the early 2010s through the mid-2010s, suggesting a deliberately layered filing strategy designed to extend protection across compound, formulation, and method-of-treatment claim categories well into the 2030s.
JENTADUETO is a commercially significant product in the global type 2 diabetes market, where fixed-dose DPP-4 inhibitor/metformin combinations command substantial prescription volume. The breadth of the asserted portfolio — five patents covering overlapping aspects of the same product — creates a high barrier for generic entrants seeking to design around any single patent. For competitors in the oral antidiabetic space, this case illustrates the enforcement risk of filing an ANDA against a brand that holds a deep, multi-layered patent estate.
Should you run an FTO against the JENTADUETO patent estate?
Any company developing, manufacturing, or seeking to market a generic linagliptin/metformin hydrochloride fixed-dose combination tablet in the US should treat the Boehringer Ingelheim patent portfolio as a live enforcement risk. This case demonstrates that Boehringer Ingelheim will file promptly on ANDA Paragraph IV certifications and that the five patents asserted here remain unchallenged on the merits. A comprehensive FTO should extend beyond these five numbers to the full linagliptin patent family, including continuation and divisional applications.
PatSnap Eureka’s FTO Search Agent can map the complete Boehringer Ingelheim linagliptin patent landscape, identify claim-level overlap with proposed generic formulations, and flag pending continuations that could extend risk beyond current expiry dates. For R&D and regulatory teams preparing ANDA submissions in the DPP-4 inhibitor space, Eureka provides claim-by-claim analysis and competitive intelligence on co-pending litigation across all five asserted patent numbers.
Run a freedom-to-operate analysis on US10022379B2 to assess your product’s exposure
Run FTO in Eureka →Similar DPP-4 inhibitor and ANDA patent cases in Delaware District Court
Explore comparable Hatch-Waxman infringement actions involving DPP-4 inhibitor and metformin combination patents filed in the District of Delaware.
What this case signals for the pharmaceutical generics IP landscape
A 16-day patent suit touching five formulation patents on a major DPP-4 inhibitor/metformin combination raises pointed questions for ANDA filers and branded pharma alike.
Ultra-short filing durations often signal Hatch-Waxman tactical manoeuvres
In Hatch-Waxman litigation, filing a patent suit within 45 days of an ANDA Paragraph IV notice triggers an automatic 30-month stay on FDA approval. A voluntary dismissal shortly after filing — before any substantive engagement — is consistent with a rapid negotiated resolution or a recalibration of litigation strategy. ANDA challengers should factor this pattern into their commercialisation timelines.
Five-patent assertion breadth signals strong defensive posture on JENTADUETO
Asserting five patents across a single combination product — spanning formulation, method of treatment, and compound claims — reflects a layered enforcement strategy typical of branded pharma defending blockbuster products. Generics entering this space should conduct thorough FTO analysis across the full patent family, not just the patents asserted in a specific action, as additional IP may be held in reserve.
Boehringer v Granules — key questions answered
Boehringer Ingelheim voluntarily dismissed all patent infringement claims against Granules India Limited without prejudice on 16 October 2024, just 16 days after filing. The dismissal was made under Rule 41(a)(1)(A)(i) before Granules India had served an answer or summary judgment motion. Five patents covering JENTADUETO linagliptin/metformin tablets were asserted.
A without-prejudice dismissal means the claims are not extinguished. Boehringer Ingelheim retains the right to re-file the same infringement action against Granules India based on any or all of the five asserted patents. No merits ruling was entered, and the patents themselves remain valid and enforceable as a matter of this proceeding.
Boehringer Ingelheim asserted five US patents: US10022379B2, US11911388B2, US9415016B2, US10973827B2, and US9155705B2. All relate to JENTADUETO, a fixed-dose combination of linagliptin and metformin hydrochloride used in the treatment of type 2 diabetes, marketed in 2.5/500 mg, 2.5/850 mg, and 2.5/1000 mg tablet strengths.
The public record does not disclose the specific reason. However, in Hatch-Waxman pharmaceutical litigation, filing suit within 45 days of a Paragraph IV ANDA notice triggers a 30-month FDA approval stay. A rapid voluntary dismissal may suggest a negotiated settlement, licensing arrangement, or a tactical decision made after the stay clock was initiated. The without-prejudice nature of the dismissal preserves Boehringer Ingelheim’s options.
JENTADUETO is Boehringer Ingelheim’s branded fixed-dose combination of linagliptin (a DPP-4 inhibitor) and metformin hydrochloride for type 2 diabetes management. As a commercially significant oral antidiabetic product, it is a natural target for ANDA generic entry. Boehringer Ingelheim holds a layered patent estate of at least five US patents covering the product, creating a high litigation barrier for any generic manufacturer seeking US market approval.
PatSnap Eureka searches patents and litigation data to answer instantly.